1 / 21

Peter A Milligan 1 & Piet Van Der Graaf 2

Influencing Early Portfolio Decision Making Using Pre-Clinical M&S: how early is too early and when is it too late?. Peter A Milligan 1 & Piet Van Der Graaf 2 1 Head of Pharmacometrics, 2 Pharmacokinetics, Dynamics & Metabolism, Pfizer. Overview.

adamma
Download Presentation

Peter A Milligan 1 & Piet Van Der Graaf 2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Influencing Early Portfolio Decision Making Using Pre-Clinical M&S: how early is too early and when is it too late? Peter A Milligan1 & Piet Van Der Graaf2 1Head of Pharmacometrics, 2Pharmacokinetics, Dynamics & Metabolism, Pfizer

  2. Overview • How early is too early and when is it too late? • For what? • Vision • What does success look like? • Historical Reality • Current Reality

  3. Vision = Integration Pathway Target Drug Disease Systems Pharmacology Systems Biology Preclinical PKPD Clinical Pharmacology Pharmaco-metrics ‘Right pathway’ ‘Right target’ ‘Right molecule’ ‘Right dose’ ‘Right patients’

  4. Van der Graaf & Danhof, 1998

  5. Translational Sciences and R&D • Across species • Within an indication • across molecules • across mechanisms • across response instruments etc. • across volunteers to patients • across patient sub populations • Across indications Translational Pathology DISEASE Translational Sciences SYSTEM DRUG Translational Pharmacology Translational Physiology

  6. Historical Reality

  7. Approach Adopted to Raise Awareness

  8. Evolution of Translational Sciences • ‘Classical’ PKPD:Compound selection • Understanding time-concentration-effect relationship • Focus on dose predictions, TI, design and interpretation of in vivo studies, in vitro-in vivo correlations • Data driven • Mechanism-based PKPD:Target validation • Understanding target pharmacology • Focus on lab objectives, biomarker selection, translational strategy • Replaces (in part) requirement to generate (in vivo) data • Systems Pharmacology:Target selection • Understanding pathway • Focus on target identification and selection & disease

  9. Decisions Taken During Selection of Monoclonal Antibody for Asthma • IgE-induced mast cell degranulation exacerbates allergic asthma and rhinitis • Anti IgE antibody, omalizumab, approved for severe asthma • Treatment success defined by reduction of free IgE levels to < 25 ng/mL • Limited treated population due to high dose and associated cost/delivery limitations • Challenge: • What is the impact of increasing in vitro affinity on the required clinical dose? • Sufficient probability (> 0.7) to support treatment of a wider population with a 50% lower dose than established agent • Follow-on candidates lack cross reactivity in preclinical species • Opportunity: • Clinical data and mechanistic PKPD model available for omalizumab • Solution: • In silico selection of candidate attributes (affinity and disposition) based on trial simulations using mechanistic PKPD model Agoram, Martin & Van Der Graaf, Drug Discovery Today (2007) 12: 1018-24 Agoram, Martin & Van Der Graaf (2007) PAGE 16 Abstr 1089

  10. Recommended dose of omalizumab (XolairR) obtained according to patient body weight and baseline total IgE • Dose (cost) • Dosing frequency • Untreated population From B.M. Prenner, J. Asthma 45, 429-436 (2008)

  11. Decisions Taken During Selection of Monoclonal Antibody for Asthma • IgE-induced mast cell degranulation exacerbates allergic asthma and rhinitis • Anti IgE antibody, omalizumab, approved for severe asthma • Treatment success defined by reduction of free IgE levels to < 25 ng/mL • Limited treated population due to high dose and associated cost/delivery limitations • Challenge: • What is the impact of increasing in vitro affinity on the required clinical dose? • Sufficient probability (≥ 0.7) to support treatment of a wider population with a 50% lower dose than established agent • Follow-on candidates lack cross reactivity in preclinical species • Opportunity: • Clinical data and mechanistic PKPD model available for omalizumab • Solution: • In silico selection of candidate attributes (affinity and disposition) based on trial simulations using mechanistic PKPD model Agoram, Martin & Van Der Graaf, Drug Discovery Today (2007) 12: 1018-24 Agoram, Martin & Van Der Graaf (2007) PAGE 16 Abstr 1089

  12. Mager, JPKPD (2001) Meno-Tetang JPET (2005) Rin(t) Rin Kon MAb Target MAb Complex + Koff Kel_MAb Kel_target Kel_Complex Non-specific Internalisation Mechanistic model used to define relationship between in vitro affinity and clinical biomarker Non-specific and specific

  13. Collate existing data required to characterise translation: Omalizumab PKPD Profile allergic asthma patients Hayashi et al. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. British Journal of Clinical Pharmacology 63:5 548–561

  14. Decisions Taken During Selection of Monoclonal Antibody for Asthma • IgE-induced mast cell degranulation exacerbates allergic asthma and rhinitis • Anti IgE antibody, omalizumab, approved for severe asthma • Treatment success defined by reduction of free IgE levels to < 25 ng/mL • Limited treated population due to high dose and associated cost/delivery limitations • Challenge: • What is the impact of increasing in vitro affinity on the required clinical dose? • Sufficient probability (≥ 0.7) to support treatment of a wider population with a 50% lower dose than established agent • Follow-on candidates lack cross reactivity in preclinical species • Opportunity: • Clinical data and mechanistic PKPD model available for omalizumab • Solution: • In silico selection of candidate attributes (affinity and disposition) based on trial simulations using mechanistic PKPD model Agoram, Martin & Van Der Graaf, Drug Discovery Today (2007) 12: 1018-24 Agoram, Martin & Van Der Graaf (2007) PAGE 16 Abstr 1089

  15. PFMAb (5x greater affinity) response at different fractions of OMZ clinical dose 0.1X 0.5X 1.0X

  16. Influencing Decision Making • Clear communication of project objectives to discovery team (with tabled assumptions) • Project guided by modelling and simulation in absence of in vivo models • Continuing expensive affinity maturation steps could be avoided: • No more than 2-2.5-fold dose reduction beyond 5-15-fold affinity increase • Model used to explore potential project opportunities beyond affinity improvement

  17. HAE1 23-fold increased binding affinity to IGE compared to omalizumab • ‘Further increases in HAE1 dose beyond 180 mg were not expected to improve the response

  18. Vision = Integration Pre-Clinical FIH FIP POC P3 Registration P4 4) Update models 3) Study Design => OCs Trial Conduct 1) Define Questions Relevant Data Volume to Models 2) Decision Criteria => PTS Relative Data Contribution to Models “compound” level “mechanism” level “indication” level

  19. Decision Theoretic Models • Quantifies the ability of protocol/program to meet stated objectives • In-depth consideration of operating characteristics • decision criteria (aka Go/No Go rules) • based on the “truth” (“if we knew the truth, would we go/no go”) • based on the data in a trial (“given the data do we go/no go”) i.e., the data-analytic decision rule • focus on false positive and negative rates (when you should GO or NO GO), probability of making a correct decision, probability of technical success • maximise probability of achieving correct decision • PTS depends on precedence, portfolio, stage of development • Beyond typical sample size methods • want to know something beyond properties of given design RG Lalonde et al, “Model-Based Drug Development”. CPT 2007;82(1):21-32 Kowalski KG et al “Model-Based Drug Development – A New Paradigm for Efficient Drug Development”. Biopharmaceutical Report 2007;15(2):2-22

  20. Approach Adopted to Raise Awareness

  21. Acknowledgements • Steven W Martin, Thomas Kerbusch, Balaji Agoram, John Ward, Jonathan L French, Kenneth G Kowalski, Mike K Smith (Pfizer) • Monica Simeoni & Maurizio Rocchetti (Accelera Nerviano Medical Sciences) • Tom Sun (& Genentech Colleagues) • Phil Lowe (& Novartis Colleagues)

More Related